https://betafinch.comenInvesting2026 Beta Finchhttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/c0aa642fe4cc5bca538799ae38a9e82f.jpghttps://betafinch.comMon, 09 Nov 2026 13:57:33 +0000Beta FinchBeta Finchcontact@betafinch.comAI-powered earnings call analysis for Amgen (AMGN). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.falsecc34e22a-45b7-5fa2-a217-3cb8add32e7btrueepisodichttps://www.spreaker.com/episode/amgen-q3-2026-earnings-analysis--76180775https://betafinch.com
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

**JORDAN:** And I'm Jordan. Today we're digging into Amgen's third quarter 2026 results — and honestly, this one's packed with pipeline news.

**ALEX:** It really is. But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good, let's get into the numbers.

**ALEX:** Amgen posted $10.4 billion in total revenue for Q3, up 8% year-over-year. And the headline stat from management: six key growth drivers — Repatha, EVENITY, TEZSPIRE, UPLIZNA, BLINCYTO, and IMDELLTRA — now make up over 70% of product sales, and together they grew 27%.

**JORDAN:** That's a meaningful shift in the revenue mix. It tells you Amgen isn't just leaning on legacy blockbusters anymore — it's a portfolio actually built around newer, faster-growing medicines. Seventeen products posted double-digit growth, and seventeen are now annualizing above a billion dollars each.

**ALEX:** On profitability, non-GAAP operating margin came in at 47%, free cash flow was $3.7 billion, and R&D spending jumped 11% — they're clearly reinvesting aggressively.

**JORDAN:** And the market liked it — shares were up over 3% on the print. Amgen also raised full-year guidance: revenue now expected between $38.9 and $39.7 billion, and non-GAAP EPS between $22.90 and $23.70. That's a confident move with just one quarter left in the year.

**ALEX:** Let's talk individual products, because there's a lot here. Repatha did $1.1 billion, up 37%, riding new cardiovascular outcomes data and updated treatment guidelines. EVENITY grew 39% to $751 million. TEZSPIRE was up 43% to $538 million.

**JORDAN:** And rare disease was a real standout — UPLIZNA sales were up 191% to $451 million. That's not a typo. Strong uptake in myasthenia gravis and really encouraging durability data in IgG4-related disease.

**ALEX:** Now let's get to what I think was the big story of the call — IMDELLTRA in small cell lung cancer.

**JORDAN:** Yeah, this is the one that had analysts buzzing. Sales more than doubled year-over-year to $406 million, but the real news was the Phase III DeLLphi-305 data presented at ESMO. In first-line maintenance, IMDELLTRA plus Imfinzi showed a median overall survival of 21.1 months versus 12.7 months for Imfinzi alone.

**ALEX:** Management described getting a standing ovation when that data was presented in Madrid. That's not something you hear often on an oncology readout.

**JORDAN:** And it's not just the efficacy — the monitoring burden is dropping too. Original label required 22 to 24 hours of monitoring for the first doses; that's now down to 6 to 8 hours, and in this newer study design, monitoring was as low as 1 to 2 hours. That could open the door to community oncology clinics actually administering this, not just big academic centers.

**ALEX:** On the call, Murdo Gordon, the commercial chief, called it a potential "cornerstone therapy" for small cell lung cancer — and noted the first-line maintenance opportunity alone could address roughly 23,000 patients in the U.S.

**JORDAN:** Beyond IMDELLTRA, they also had positive Phase III results for TEZSPIRE in eosinophilic esophagitis and for dazodalibep in Sjögren's disease — a condition with zero approved disease-modifying therapies today. Three positive Phase III readouts in one quarter is a strong batting average for an R&D org.

**ALEX:** There was good Q&A color too. On MariTide, Amgen's obesity candidate, CFO Thomas Dittrich — in his first call as CFO — confirmed they're sticking with about $2.6 billion in CapEx this year, partly to prepare manufacturing for a potential MariTide launch.

**JORDAN:** And when asked about tolerability,

This episode includes AI-generated content.]]>AMGN-Q3-2026-enWed, 04 Nov 2026 22:14:22 +0000trueBeta FinchMore earnings analysis: https://betafinch.com ────────── **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex. **JORDAN:** And I'm Jordan. Today we're digging into Amgen's third quarter 2026 results — and honestly, this one's...https://betafinch.com
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

**JORDAN:** And I'm Jordan. Today we're digging into Amgen's third quarter 2026 results — and honestly, this one's packed with pipeline news.

**ALEX:** It really is. But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good, let's get into the numbers.

**ALEX:** Amgen posted $10.4 billion in total revenue for Q3, up 8% year-over-year. And the headline stat from management: six key growth drivers — Repatha, EVENITY, TEZSPIRE, UPLIZNA, BLINCYTO, and IMDELLTRA — now make up over 70% of product sales, and together they grew 27%.

**JORDAN:** That's a meaningful shift in the revenue mix. It tells you Amgen isn't just leaning on legacy blockbusters anymore — it's a portfolio actually built around newer, faster-growing medicines. Seventeen products posted double-digit growth, and seventeen are now annualizing above a billion dollars each.

**ALEX:** On profitability, non-GAAP operating margin came in at 47%, free cash flow was $3.7 billion, and R&D spending jumped 11% — they're clearly reinvesting aggressively.

**JORDAN:** And the market liked it — shares were up over 3% on the print. Amgen also raised full-year guidance: revenue now expected between $38.9 and $39.7 billion, and non-GAAP EPS between $22.90 and $23.70. That's a confident move with just one quarter left in the year.

**ALEX:** Let's talk individual products, because there's a lot here. Repatha did $1.1 billion, up 37%, riding new cardiovascular outcomes data and updated treatment guidelines. EVENITY grew 39% to $751 million. TEZSPIRE was up 43% to $538 million.

**JORDAN:** And rare disease was a real standout — UPLIZNA sales were up 191% to $451 million. That's not a typo. Strong uptake in myasthenia gravis and really encouraging durability data in IgG4-related disease.

**ALEX:** Now let's get to what I think was the big story of the call — IMDELLTRA in small cell lung cancer.

**JORDAN:** Yeah, this is the one that had analysts buzzing. Sales more than doubled year-over-year to $406 million, but the real news was the Phase III DeLLphi-305 data presented at ESMO. In first-line maintenance, IMDELLTRA plus Imfinzi showed a median overall survival of 21.1 months versus 12.7 months for Imfinzi alone.

**ALEX:** Management described getting a standing ovation when that data was presented in Madrid. That's not something you hear often on an oncology readout.

**JORDAN:** And it's not just the efficacy — the monitoring burden is dropping too. Original label required 22 to 24 hours of monitoring for the first doses; that's now down to 6 to 8 hours, and in this newer study design, monitoring was as low as 1 to 2 hours. That could open the door to community oncology clinics actually administering this, not just big academic centers.

**ALEX:** On the call, Murdo Gordon, the commercial chief, called it a potential "cornerstone therapy" for small cell lung cancer — and noted the first-line maintenance opportunity alone could address roughly 23,000 patients in the U.S.

**JORDAN:** Beyond IMDELLTRA, they also had positive Phase III results for TEZSPIRE in eosinophilic esophagitis and for dazodalibep in Sjögren's disease — a condition with zero approved disease-modifying therapies today. Three positive Phase III readouts in one quarter is a strong batting average for an R&D org.

**ALEX:** There was good Q&A color too. On MariTide, Amgen's obesity candidate, CFO...]]>352falsefullhttps://www.spreaker.com/episode/coming-soon-amgen-amgn-earnings-analysis--75739707
This episode includes AI-generated content.]]>https://api.spreaker.com/episode/75739707Tue, 13 Oct 2026 02:01:46 +0000trueBeta FinchBeta Finch's AI-powered earnings call analysis for Amgen (AMGN) is coming soon. Follow the show to get the first full episode as soon as Amgen reports.
This episode includes AI-generated content.]]>121falsefull